Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > NASH collaboration
View:
Comment by SPCEO1 on Nov 17, 2021 10:20am
Early stage and apparently no money changing hands - so I don't think this represents much that would impact TH's negotiations with potential partners. But at least something is happening inthe NASH space.
Comment by jeffm34 on Nov 17, 2021 11:08am
It was part of this deal. It's one of the 3 additional targets thrown in. I think if TH makes partnership deals with the Sortilin platform it could be structured similarly. The broad applications of the program will require companies to explore all kinds of chemo drugs linked to the peptide in many types of cancers.  https://www.businesswire.com/news/home/20181004005195/en/Arrowhead ...more  
Comment by qwerty22 on Nov 17, 2021 11:16am
Here's the original agreement from 2018, lot of money there. Looks like the original agreement was for a Hep B drug with the option for 3 more drugs. I guess this is reporting now that one of those 3 is a NASH drug. I guess as you say even though investors may have cooled around NASH at least there is still evidence of big Pharma interest. https://ir.arrowheadpharma.com/news-releases/news ...more  
Comment by Wino115 on Nov 17, 2021 11:58am
Took stock from 4-ish to 65-ish -- 15x your money.  Let us dream!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities